Kamada Ltd. (KMDA)
USD 6.28
(3.46%)
USD 6.28
(3.46%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 52.59 Million USD | 12.61% |
| 2022 | 46.7 Million USD | 53.99% |
| 2021 | 30.32 Million USD | -36.22% |
| 2020 | 47.55 Million USD | -4.39% |
| 2019 | 49.73 Million USD | 19.93% |
| 2018 | 41.47 Million USD | 29.24% |
| 2017 | 32.08 Million USD | 48.21% |
| 2016 | 21.65 Million USD | 35.27% |
| 2015 | 16 Million USD | 2.47% |
| 2014 | 15.61 Million USD | -40.85% |
| 2013 | 26.4 Million USD | 16.37% |
| 2012 | 22.69 Million USD | 44.36% |
| 2011 | 15.72 Million USD | 158.9% |
| 2010 | 6.07 Million USD | 816.74% |
| 2009 | -847.15 Thousand USD | -1296.0% |
| 2008 | 70.83 Thousand USD | -97.76% |
| 2007 | 3.16 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 18.68 Million USD | 12.56% |
| 2024 Q1 | 16.6 Million USD | 9.43% |
| 2023 Q4 | 15.17 Million USD | 2.48% |
| 2023 FY | 52.59 Million USD | 12.61% |
| 2023 Q2 | 14.43 Million USD | 21.94% |
| 2023 Q3 | 14.8 Million USD | 2.54% |
| 2023 Q1 | 11.83 Million USD | -22.58% |
| 2022 Q4 | 15.29 Million USD | 18.81% |
| 2022 Q3 | 12.87 Million USD | 77.76% |
| 2022 FY | 46.7 Million USD | 53.99% |
| 2022 Q1 | 11.3 Million USD | 71.37% |
| 2022 Q2 | 7.24 Million USD | -35.94% |
| 2021 Q4 | 6.59 Million USD | 15.1% |
| 2021 Q2 | 9.07 Million USD | 1.58% |
| 2021 Q3 | 5.73 Million USD | -36.84% |
| 2021 FY | 30.32 Million USD | -36.22% |
| 2021 Q1 | 8.93 Million USD | -12.14% |
| 2020 Q4 | 10.16 Million USD | -31.41% |
| 2020 Q2 | 11.11 Million USD | -2.93% |
| 2020 Q1 | 11.45 Million USD | -5.28% |
| 2020 Q3 | 14.82 Million USD | 33.34% |
| 2020 FY | 47.55 Million USD | -4.39% |
| 2019 FY | 49.73 Million USD | 19.93% |
| 2019 Q3 | 12.86 Million USD | -5.41% |
| 2019 Q4 | 12.08 Million USD | -6.02% |
| 2019 Q2 | 13.6 Million USD | 21.6% |
| 2019 Q1 | 11.18 Million USD | -47.38% |
| 2018 Q1 | 7.01 Million USD | -39.67% |
| 2018 Q4 | 21.25 Million USD | 743.83% |
| 2018 Q3 | 2.51 Million USD | -76.39% |
| 2018 FY | 41.47 Million USD | 29.24% |
| 2018 Q2 | 10.67 Million USD | 52.08% |
| 2017 Q3 | 6.44 Million USD | -44.95% |
| 2017 FY | 32.08 Million USD | 48.21% |
| 2017 Q4 | 11.63 Million USD | 80.37% |
| 2017 Q2 | 11.71 Million USD | 409.66% |
| 2017 Q1 | 2.29 Million USD | -53.74% |
| 2016 FY | 21.65 Million USD | 35.27% |
| 2016 Q1 | 4.77 Million USD | -42.2% |
| 2016 Q2 | 5.62 Million USD | 17.84% |
| 2016 Q3 | 6.27 Million USD | 11.49% |
| 2016 Q4 | 4.96 Million USD | -20.84% |
| 2015 Q2 | 3.64 Million USD | 828.57% |
| 2015 Q4 | 8.26 Million USD | 122.9% |
| 2015 Q3 | 3.7 Million USD | 1.87% |
| 2015 Q1 | 392 Thousand USD | -95.13% |
| 2015 FY | 16 Million USD | 2.47% |
| 2014 Q3 | 4.37 Million USD | 6728.79% |
| 2014 Q1 | 3.26 Million USD | -63.21% |
| 2014 FY | 15.61 Million USD | -40.85% |
| 2014 Q2 | -66 Thousand USD | -102.02% |
| 2014 Q4 | 8.04 Million USD | 83.95% |
| 2013 Q3 | 5.92 Million USD | -20.16% |
| 2013 Q2 | 7.42 Million USD | 76.9% |
| 2013 FY | 26.4 Million USD | 16.37% |
| 2013 Q4 | 8.86 Million USD | 49.64% |
| 2013 Q1 | 4.19 Million USD | -48.11% |
| 2012 Q4 | 8.08 Million USD | 41.68% |
| 2012 FY | 22.69 Million USD | 44.36% |
| 2012 Q2 | 3.28 Million USD | 0.0% |
| 2012 Q3 | 5.7 Million USD | 73.96% |
| 2011 FY | 15.72 Million USD | 158.9% |
| 2010 FY | 6.07 Million USD | 816.74% |
| 2009 FY | -847.15 Thousand USD | -1296.0% |
| 2008 FY | 70.83 Thousand USD | -97.76% |
| 2007 FY | 3.16 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 83.876% |
| Embecta Corp. | 749.9 Million USD | 92.987% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 82.774% |
| Dynavax Technologies Corporation | 182.11 Million USD | 71.121% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 28.021% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 89.274% |
| PainReform Ltd. | -15 Thousand USD | 350718.3% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -76.77% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -530.671% |
| SCYNEXIS, Inc. | 124.51 Million USD | 57.763% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -9393.772% |
| Cosmos Health Inc. | 4.34 Million USD | -1109.148% |
| Journey Medical Corporation | 52.52 Million USD | -0.137% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -530.671% |
| Safety Shot Inc | -74.45 Thousand USD | 70735.058% |
| Alpha Teknova, Inc. | 10.29 Million USD | -410.808% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 87.787% |
| Bright Green Corporation | -237.01 Thousand USD | 22289.534% |
| Procaps Group, S.A. | 239.56 Million USD | 78.047% |
| Theratechnologies Inc. | 62.12 Million USD | 15.349% |
| Harrow Health, Inc. | 90.55 Million USD | 41.92% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -1008.382% |
| Biofrontera Inc. | 16.62 Million USD | -216.309% |
| DURECT Corporation | 6.83 Million USD | -669.913% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 89.958% |
| Cronos Group Inc. | 6.99 Million USD | -652.303% |
| OptiNose, Inc. | 62.35 Million USD | 15.655% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 88.079% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 17457.342% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -1621.996% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 83.023% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | -874.93% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -57.059% |
| Radius Health, Inc. | 307.71 Million USD | 82.908% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -421.863% |
| ProPhase Labs, Inc. | 16.23 Million USD | -223.867% |
| Phibro Animal Health Corporation | 312.48 Million USD | 83.17% |
| Procaps Group S.A. | 239.56 Million USD | 78.047% |
| Alvotech | -69.42 Million USD | 175.758% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -3939.381% |
| Viatris Inc. | 6.43 Billion USD | 99.183% |
| Rockwell Medical, Inc. | 8.7 Million USD | -504.237% |
| Aytu BioPharma, Inc. | 54.58 Million USD | 3.652% |
| SIGA Technologies, Inc. | 122.09 Million USD | 56.924% |
| Tilray Brands, Inc. | 223.35 Million USD | 76.453% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -25.67% |
| Shineco, Inc. | 882.16 Thousand USD | -5861.761% |
| PetIQ, Inc. | 252.74 Million USD | 79.191% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 7153.862% |
| Incannex Healthcare Limited | 12 Thousand USD | -438172.875% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 97.153% |
| Alimera Sciences, Inc. | 61.17 Million USD | 14.022% |
| Silver Spike Investment Corp. | 8.1 Million USD | -549.085% |
| Assertio Holdings, Inc. | 125.04 Million USD | 57.942% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 772273.616% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -1154.847% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | -702.208% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 2282.112% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -93.948% |
| Hempacco Co., Inc. | -1.21 Million USD | 4425.655% |
| Talphera, Inc. | -4.89 Million USD | 1174.418% |
| Alvotech | -69.42 Million USD | 175.758% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | 76.275% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 92.588% |
| Currenc Group, Inc. | 17.35 Million USD | -203.018% |
| Indivior PLC | 907 Million USD | 94.201% |
| Evoke Pharma, Inc. | 4.97 Million USD | -956.344% |
| Flora Growth Corp. | 17.73 Million USD | -196.498% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 2282.112% |
| Evolus, Inc. | 140.52 Million USD | 62.574% |
| HUTCHMED (China) Limited | 453.55 Million USD | 88.404% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 84.71% |
| Akanda Corp. | 111.44 Thousand USD | -47089.966% |